Scribe Therapeutics, targeting cardiometabolic diseases with its gene therapy STX-1150, saw its stock rise over 10% despite no new company news. STX-1150 aims to lower cholesterol by silencing PCSK9, with preclinical data showing significant LDL-C reductions lasting at least two years in primates. The company is funded through 2029 and has partnerships with Sanofi and Eli Lilly, offering potential milestone payments. Key upcoming catalysts include Phase 1 safety data expected in early 2027, though risks remain due to reliance on a single asset and manufacturing challenges.
Scribe Therapeutics gene therapy news is presented with Pluang's Health sector market data for context. Of 150 priced Health-sector US stocks on Pluang, 95 rose and 46 fell today. Notable movers include Ascendis Pharma A/S at USD 219.09 with a 3.48% decline and AstraZeneca plc at USD 167.07 with a 3.11% gain, as of Oct 15, 2026 19:31 WIB.
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
ONEOK completed a $4.425 billion acquisition of Brazos Midstream's natural gas assets, doubling its processing capacity in the Permian Midland Basin to about 2.3 billion cubic feet per day. The deal secures 600,000 acres under long-term contracts, st...
Charles Schwab reported Q3 earnings per share of $1.69, beating estimates despite slightly missing revenue forecasts with $7.17 billion. The quarter marked a 17% revenue increase year-over-year and a 23% rise in net income to $2.91 billion, driven by...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
